🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 9 of 16

  1. Selinexor

    Karyopharm Therapeutics Inc

    Diabetic Foot Ulcers

    phase 2 small molecule terminated

    1 trial

  2. Semaglutide (Rybelsus®)

    The First People's Hospital of Lianyungang

    Obesity-related Male Infertility

    phase 2 small molecule active

    1 trial

  3. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Genetic Obesity

    phase 2 small molecule completed

    2 trials

  4. Setmelanotide

    Rhythm Pharmaceuticals Netherlands B.V.

    Overweight and Obesity

    phase 2 small molecule completed

    1 trial

  5. Sotagliflozin

    LEXICON PHARMACEUTICALS, INC.

    Type 1 Diabetes

    phase 2 small molecule active

    2 trials

  6. Suspension of autologous mononuclear cells separated from bone marrow aspirate

    The George Institute

    chronic limb-threatening ischemia, diabetic foot ulcers

    phase 2 small molecule active

    1 trial

  7. Suzetrigine

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  8. TAK-128

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule terminated

    2 trials

  9. TAK-272

    Takeda

    Type 2 Diabetes Mellitus and Microalbuminuria

    phase 2 small molecule completed

    1 trial

  10. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  11. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  12. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  13. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  14. TAK-954

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  15. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  16. TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, IOHEXOL , TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  17. TTP054

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  18. TTP273

    vTv Therapeutics

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. TTP399

    vTv Therapeutics

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    1 trial

  20. TTP399 400 mg

    vTv Therapeutics

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  21. TTP435

    vTv Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  22. TVB-2640

    Sagimet Biosciences

    Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease

    phase 2 small molecule completed

    1 trial

  23. TVB-2640 25 mg (US)

    Sagimet Biosciences

    MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

    phase 2 small molecule completed

    1 trial

  24. Tangweian Recipe

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Diabetic Gastroenteropathy

    phase 2 small molecule active

    1 trial

  25. Thiogamma 600 mg Filmtabletten, Benfogamma Forte, 300 mg, tabletki powlekane

    Lacuna Pharma Pty Ltd

    Diabetic sensorimotor polyneuropathy (DSPN)

    phase 2 small molecule active

    1 trial

  26. Tirzepatide

    Regeneron UK Limited

    Obesity

    phase 2 small molecule completed

    1 trial

  27. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Nisotirotide, placebo to match LY, Tirzepatide

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  28. Tradipitant

    Vanda Pharmaceuticals Netherlands B.V.

    Obesity

    phase 2 small molecule completed

    1 trial

  29. Trevogrumab-Part A

    Regeneron UK Limited

    Obesity

    phase 2 small molecule active

    1 trial

  30. UBT251

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule active

    1 trial

  31. UBT251

    United Therapeutics Europe Ltd

    Metabolic Dysfunction-associated Steatohepatitis (MASH)

    phase 2 small molecule active

    1 trial

  32. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Obesity &Amp; Overweight

    phase 2 small molecule completed

    1 trial

  33. UBT251 Injection 2.0 mg and UBT251 Injection Placebo

    United Therapeutics Europe Ltd

    Type 2 Diabetes Mellitus (T2DM)

    phase 2 small molecule completed

    1 trial

  34. VC-02 Combination Product

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus With Hypoglycemia

    phase 2 other completed

    1 trial

  35. VK2809

    Viking Therapeutics

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  36. VX-264

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  37. VX-264 Implant

    Vertex Pharmaceuticals (Australia) Pty.

    Type 1 Diabetes Mellitus

    phase 2 small molecule active

    1 trial

  38. VX-993

    Vertex Pharmaceuticals (Australia) Pty.

    Diabetic Peripheral Neuropathic Pain

    phase 2 small molecule active

    1 trial

  39. Vi-Siblin S granulat, alli 60 mg hard capsules, Dietary fibre supplement Placebo - Maltodextrin

    Lacuna Pharma Pty Ltd

    Obesity

    phase 2 small molecule active

    1 trial

  40. Yogurt smoothie with BB-12

    United Therapeutics Europe Ltd

    Metabolic Syndrome

    phase 2 small molecule active

    1 trial

  41. Zemplar (paricalcitol ) capsules

    Abbott Australasia Pty Ltd

    Diabetic Nephropathy

    phase 2 small molecule completed

    1 trial

  42. albiglutide

    GlaxoSmithKline

    Diabetes Mellitus, Type 2

    phase 2 mab completed

    1 trial

  43. aleniglipron or placebo

    Structure Therapeutics

    Obesity

    phase 2 small molecule completed

    1 trial

  44. cagrilintide semaglutide, Placebo + Placebo, cagrilintide semaglutide, semaglutide, cagrilintide, cagrilintide, cagrilintide semaglutide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, FINERENONE , DAPAGLIFLOZIN , semaglutide, cagrilintide, ENALAPRIL , cagrilintide, cagrilintide, cagrilintide semaglutide

    NovoThirteen

    Chronic Kidney Disease, Type 2 diabetes

    phase 2 small molecule active

    1 trial

  45. efinopegdutide, efinopegdutide, efinopegdutide, Placebo to MK-6024, efinopegdutide

    Merck Sharp and Dohme

    Metabolic Dysfunction-Associated Steatohepatitis

    phase 2 small molecule active

    1 trial

  46. linagliptin low dose

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 2 small molecule completed

    1 trial

  47. metformin

    BRIGHT MINDS BIOSCIENCES INC.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  48. metformin

    Takeda

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.